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Purpose: An increased incidence of bleeding complications has been observed after 
supracefiac aortic clamping (SCC). This study was performed to identify possible hemo- 
static abnormalities that contribute to this problem. 
Methods: A prospective cohort study over a 3-month period was performed by comparing 
hemostatic parameters in 10 consecutive patients who required elective SCC With those 
of eight concurrent randomly selected control subjects who required infrarenal clamping 
(IRC) for abdominal aortic reconstruction. Measures of coagulation, fibrinolysis, platelet 
fimction, temperature, hemodilution, and hepatic function were performed at selected 
times before, during, and after operation. 
Results: Aaleurysm size, fibrinogen, D-dimers, prothrombin, partial thromboplastin time, 
platelet counts, bleeding times, hemodilution, and temperature were comparable in both 
groups. Patients in the SCC group, however, consistently developed a primary fibrino- 
lyric state within 20 minutes after supraceliac clamping, reflected by significantly de- 
creased euglobulin clot lysis times (ECLT; p < 0.0001), elevated tissue plasminogen 
activator (t-PA) levels (p < 0.0006), elevated t-PA-to-plasminogen activator inhibitor-1 
ratios (p < 0.0001), and reduced ~2-antiplasmin levels (p < 0.002). SCC produced 
hepatocellular injury documented by elevations in both aspartate transaminase (p < 
0.0001) and lactate dehydrogenase (p < 0.009). 
Conclusions: SCC rapidly induces a primary fibrinolytic state manifested by increased circu- 
lating t-PA, reduced ot2-antiplasmin, and increased fibrinolytic activator-to-inhibitor ratios. 
These effects may be a result of hepatic hypoperfusion caused by SCC leading to insufficient 
clearance of t-PA. Antifibrinolytic agents may be of benefit if bleeding develops after aortic 
procedures that require supraceliac damping. (J Vasc Surg 1997;25:244-54.) 
Supraceliac aortic clamping (SCC) is required for 
the repair of thoracoabdominal aneurysms (TAA) 
and abdominal aortic aneurysms (AAA) or occlusive 
disease involving the pararenal segment.1 SCC is safe, 
especially in relation to suprarenal clamping. 2 Some 
patients, however, develop excessive bleeding 3 that is 
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at times resistant to routinc replacement therapy with 
platelets and plasma. Several possible mechanisms for 
such bleeding have been suggested, including plate- 
let dysfunction, hemodilution, hypothermia, and 
consumptive coagulopathy. 4 
When the supraceliac aorta is clamped, hepatic 
perfusion is reduced, resulting in a situation anala- 
gous to the anhepatic phase oforthotopic liver trans- 
plantation (OLT). During OLT, levels of endoge- 
nous tissue plasminogen activator (tPA) are elevated, 
and excessive fibrinolytic activation contributes to 
abnormal bleeding. 5-7 To test the hypothesis that 
SCC produces aprimary fibrinolyti c state by a similar 
mechanism, we compared hemostatic function pro- 
spectively in two cohorts of patients who underwent 
planned SCC or infrarenal clamping (IRC) for elec- 
tive abdominal aortic reconstruction. 
PATIENTS AND METHODS 
After obtaining informed consent, 10 consecu- 
tive patients who underwent planned SCC for dec- 
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Fig. 1. Study protocol: Mean time after induction of an- 
esthesia for all 18 patients is indicated on the abscissa. 
Blood samples were obtained at eight points: before induc- 
tion of anesthesia (T1), just before heparinization and 
proximal clamping (T2), just before proximal clamp was 
removed (T3), 10 minutes after clamp was shifted to graft 
for performance of distal anastomosis (T4), 30 (T5) and 60 
(T6) minutes after all clamps were removed and lower 
extremities perfused, and 180 (3 hours, T7) and 720 (12 
hours, TS) minutes after operation w s completed. Dura- 
tion of proximal and distal clamping is dicated by dark 
and light shading, respectively. 
tive AAA repair (eight) or aortofemoral bypass (two) 
were prospectively compared with eight patients who 
underwent conventional AAA repair over a concur- 
rent 3-month period. All patients were heparinized 
during clamping with a loading dose of 125 units/kg 
and supplemented, as needed, to ensure an activated 
clotting time (ACT) of 300 seconds or more; heparin 
was reversed with protaminc sulfate after release of 
clamps to achieve an ACT within 10% of baseline. 
Fluid administration and general intraoperative care 
were performed as clinically indicated and were not 
dictated by the study protocol. Packed red blood 
cells and platelets were transfused as needed to keep 
the hematocrit level above 30% and platelet count 
above 70,000/mcl. Patients received vasodilators 
and inotropic support as indicated to maintain he- 
modynamic stability, and patients in the SCC group 
received 25 gm of mannitol immediately before un- 
clamping. 
Fig. 1 illustrates the experimental design. Arterial 
blood was collected into 7-ml tubes containing 3.2% 
sodium citrate, 15% ethylenediamine tetraacetic acid 
(EDTA) and without additive at eight times: before 
anesthesia (T1), before heparinization (T2), just be- 
fore release of the proximal clamp (T3), 10 minutes 
after the clamp was repositioned to the graft for 
performance of the distal anastomosis (T4), at 30 
(T5) and 60 minutes (T6) after unclamping, and at 
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Fig. 2. Schematic version of fibrinolytic system, t-PA is 
major enzyme responsible for cleavage of plasminogen, 
and PAI-1 is its major inhibitor, c~2-AP binds to and 
inactivates plasmin. Plasmin degrades fibrinogen, fibrid, 
and formed clot, yielding FDP and D-dimers. 
180 (3 hours, T7) and 720 (12 hours, T8) minutes 
after the end of the operation. Serum was prepared 
for measurement of blood urea nitrogen (BUN), 
creatinine l vel, aspartate ransaminase (AST), lactate 
dehydrogenase (LDH), alkaline phosphatasc, biliru- 
bin, amylase, lipase, and total protein using auto- 
mated analysis. Hematocrit and platelet counts were 
measured in EDTA anticoagulated blood, and other 
tests ofhemostasis in citrated plasma. Bleeding times 
were determined the evening before operation and 3 
to 5 hours after operation, and blood loss from 
incision to clamping, during proximal and distal 
clamping, and from unclamping until completion of 
the operation were recorded, as were the tempera- 
ture and all fluids required. An estimate of the degree 
of hemodilution ("dilution factor") was made by 
measuring the relative change in the total protein 
concentration ateach time period. 
Fibrinolytic mediators measured were tissue plas- 
minogen activator (t-PA), the major endogenous 
enzyme responsible for the cleavage of plasminogen 
to plasmin, plasminogen activator inhibitor-1 (PM- 
1), the major circulating inhibitor of t-PA, and c~2- 
antiplasmin (ot2-AP), the major inhibitor ofplasmin 
(Fig. 2). The euglobulin clot lysis time (ECLT) was 
used as a global measure of fibrinolytic activity. 
Prothrombin (PT) and activated partial throm- 
boplastin times (aPTT) were measured using the 
Coag-A-Mate (Organon Teknika Corp., Durham, 
N.C.). Fibrinogen was assayed by the method of 
Clauss, 8 and ECLT as described in Nilsson and 
Olow. 9 t-PA, D-dimer, and PAI-1 levels were mea- 
sured by enzyme-linked immunosorbent assay 
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Table I. Group characteristics 
SCC IRC 
(~=~o) (n=8) p 
Age (years) 72 -+ 2 67 + 2 0.12 
(63-81) (61-76) 
AAA size (cm)]'. 6.0 + 0.4 6.2 +-_ 0.4 0.75 
(4.5-8.0) (4.9-8.0) 
ASA class 2.5 _+ 0.2 2.6 + 0.2 0.68 
CAD (%) 90% 75% 0.72 
COPD (%) 10% 12.5% 0.87 
Baseline creatinine l vel (mg/dl) 1.0 +- 0.1 0.9 + 0.1 0.64 
SCC time (min) 34 + 34 0 
(20-53) 
Total clamp time (min) 81 ± 7 59 ± 10 .08 
(47-126) (33-109) 
Operative time (min) 239 ± 18 191 ± 33 0.19 
(143-315) (79-361) 
Continuous variables expressed as mean +- standard error with 
ranges in parentheses, if appropriate. 
ASA, American Society of Anesthesiology; CAD, coronary artery 
disease; COPD, chronic obstructive pulmonary disease. 
]Only the eight patients in SCC group with aneurysms are in-
cluded in comparison of AAA size. 
(American Bioproducts, Parsippany, N.J.). Fibrin 
degradation products (FDP) were measured using 
the FDP Plasma Kit (American Bioproducts, Parsip- 
paw, N.J.), a semiquantitative m thod using latex 
particles coated with monoclonal ntibodies to FDP. 
R2-AP was measured using a chromogenic assay 
(Chromogenix, Franldin, Ohio) using the substrate 
S-2251. No measurements o her than ACT and PTT 
are affected by heparin. 
Data analysis was performed on a Power Macin- 
tosh 7100/66AV (Apple Computer, Cupertino, 
Calif.) using Statview 4.02 (Abacus Concepts, Berke- 
ley, Calif.). Repeated measures analysis of variance 
(ANOVA) was used for overall comparisons between 
groups, and further analysis performed using X 2 and 
Fisher's exact tests (nominal data) and individual t
tests. Significance was set at p < 0.025 for situations 
in which multiple comparisons were performed. 
Continuous data obtained at discrete intervals 
(ECLT and FDP) were recorded for ANOVA as the 
interval mean. Because of varying clamp times, the 
abscissa of each graph is expressed as the overall 
mean time for each interval for all 18 patients. 
RESULTS 
Preoperative clinical parameters, including AAA 
size, age, underlying medical problems, and overall 
physiologic status were comparable between the two 
groups (Table I). The 10 SCC patients had pararenal 
disease that prohibited clamping below the renal 
arteries as judged by computed tomographic scan 
and angiogram. SCC time averaged 34 + 3 minutes 
(range, 20 to 53 minutes). The total clamp (81 + 7 
vs 59 + 10 minutes) and total operative times 
(239 +- 18 vs 191 + 33 minutes) were longer in the 
SCC group but did not reach statistical significance. 
Giver and pancreatic function, AST and LDH 
both increased in the SCC group, but remained 
constant in the IRC patients (Fig. 3). A difference in 
AST levels was initially seen in the first sample after 
SCC (34 + 4 vs 18 -+ 2 IU/L;  p < 0.005). Mean 
AST and LDH increased inthe SCC group until 180 
minutes after operation, then declined. There were 
no significant changes in the AST or LDH in the 
IRC group. There were only minor changes in alka- 
line phosphatase and bilirubin levels in either group. 
Small but significant elevations i  both amylase 
(47 + 4 to 129 + 36 IU/L; p < 0.0001) and lipase 
(103 + 36 to 731 + 296 IU/L;  p = 0.03) occurred 
in patients taken as a whole, although differences 
according to clamp position did not occur. 
Coagulation and fibrinolysis. Blood loss be- 
fore clamping, during the proximal and distal anasto- 
moses, and until closure, as well as overall blood loss, 
total fluids, crystalloid, and blood products required, 
did not differ between groups (Table II), although 
the small sample size may have made subtle differ- 
ences undetectable. Blood loss was greatest in both 
groups during performance of the proximal anasto- 
mosis. Hemodilution, as measured by short-term 
changes in total protein concentrations, was similar 
in both SCC and IRC patients, reaching amaximum 
of 49% _-+_ 3% and 47% + 2%, respectively, by approx- 
imately 120 minutes after the start of the operation. 
Postoperative blood and fresh frozen plasma require- 
ments were minimal in all patients, mad no patient 
required platelets or any other treatment for blceding 
(Table II). Hypothermia (minimum 35.1 +- 0.4 ° C) 
occurred in all patients, but overall temperature 
curves were similar between groups. 
Hemostatic parameters before operation were 
normal except for overall elevations in fibrinogen 
(392 -+ 17; normal, 200 to 400 mg/dl) and D-dimer 
(1466 + 377; normal, <400 ng/ml), but there were 
no differences between groups. Marked alterations in
hemostatic parameters occurred uring operation in 
both groups. PT and PTT increased in all patients 
after heparinization and hemodilution. PTT re- 
turned to normal after protamine administration, 
while mean postoperative PT remained elevated 
(15.5 -+ 0.5 scconds 180 minutcs after operation) 
until 720 minutes (12 hours) after the operation was 
completed (Table II); no differences were seen be- 
tween groups. The platelet count decreased in all 
patients to approximately one third of the baseline 
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Fig.  3. AST  (left) and LDH (right) dur ing  s tudy  protocol .  Data  presented  as mean + standard 
error. Overall significance assessed by repeated measures  ANOVA,  and each point in time is 
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Table II. Blood loss, fluid replacement, and postoperative coagulation status 
SCC IR C 
(n=lO) (n=8) p 
Total EBL (ml) 3114 ± 518 3031 -- 560 0.92 
Before clamping 189 ± 43 191 -- 62 0.97 
Proximal anastomosis 1518 + 302 1555 -- 488 0.95 
Distal anastomosis 814 _+ 220 686 -- 224 0.69 
All clamps offto closure 594 + 154 600 -- 276 0.99 
Total intraoperative fluids (ml) 9960 -4- 713 8285 _+ 1059 0.20 
Crystalloid (ml) 7030 -+ 602 5925 ± 1097 0.37 
Cell saver blood (ml) 765 + 153 904 _+ 176 0.56 
Banked blood (ml) 1290 _+ 129 588 -- 190 p = .01 
Fluids/hour operation (ml/hr)  2500 _+ 133 2602 +_ 303 0.90 
fntraoperative UOP (ml) 968 + 159 771 ± 203 0.45 
UOP/hour  operation (ml/hr)  243 +- 79 242 ± 90 0.99 
Total (pre- and postoperative): 
FFP (units) 0.8 + 0.3 0.3 -- 0.3 0.22 
(0-2) (0-2) 
Platelets (units) 0 0 
Blood (units) 6.7 ± 0.8 5.6 ± 1.3 0.47 
(2-11) (1-12) 
Postoperative ACT (sec) 120 ± 5 118 ± 7 0.81 
Postoperative PT (sec) 15.8 -+ 0.9 15.2 _+ 0.4 0.58 
Postoperative PTT (sec) 32.7 ± 4.8 28.3 ± 1.4 0.44 
Continuous variables expressed as mean _+ standard error. 
EBL, estimated blood loss, UOP = urine output, FFP, fresh frozen plasma. 
value by 30 minutes after proximal clamping 
(211,000 + 15,000 to 127,000 -+ 12,000/mcl) ,  but 
mean values never fell below l l0 ,000/mc l .  The 
largest drop (26%) occurred after proximal clamping, 
and no differences were seen between groups. Post- 
operative bleeding times (SCC, 7.3 + 1.2; IRC, 
6.9 + 0.6 minutes) were not different. The decrease 
in fibrinogen was of similar magnitude to that of the 
platelet count, declining from a baseline of 392 + 17 
to a nadir of  212 _ 22 mg/d l  at 1 hour after all 
clamps were released. It remained low throughout 
the period o f  observation but never fell below 200 
mg/dl .  Again, the greatest drop (22%) occurred after 
the proximal clamp was applied, and no difference 
was seen between groups. D-dimer and FDP in- 
creased modestly in patients who underwent IRC. 
There was a significant increase in FDP in the SCC 
group (6 -+ 3 to 34 - 10 mcg/ml)  relative to that in 
the IRC group (3 --- 0 to 11 + 3 mcg/ml ;p  = 0.02). 
Although baseline D-dimer levels were somewhat 
higher in the SCC (2015 _+ 629 ng/ml)  as compared 
with the IRC (78I - 137 ng/ml)  patients, variabil- 
ity was wide and the increase over time (SCC, 1675; 
IRC, 1650 ng/ml)  did not differ between groups. 
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Fig. 4. ECLT (left) and t-PA levels (right) during study protocol. Data presented as mean +_ 
standard error. Overall significance assessed by repeated measures ANOVA, and each point in 
time is analyzed using t tests. *Significance at p < 0.025 (because of multiple comparisons). 
Changes in fibrinolytic parameters were promi- 
nent in the SCC group beginning at the point of 
supraceliac lamping. No patient had evidence of 
fibrinolysis (ECLT >150 minutes) before clamping. 
No significant changes in the ECLT of samples 
drawn at any time during or after operation occurred 
in IRC patients (Fig. 4). In contrast, the ECLT was 
significantly shortened in the SCC group as early as 
20 minutes after proximal clamping (60 _+ 12 vs 
142 _+ 6 minutes; p < 0.0001). This depression 
persisted uring distal clamping (60 + I2 vs 142 + 6 
minutes; p < 0.0001), but normalized 30 minutes 
after all clamps were removed. Nine of the 10 SCC 
patients had shortened ECLT during clamping, 
whereas no sample at any time in any patient who 
underwent IRC lysed before 2 hours. 
There was a corresponding increase in the t-PA 
level immediately after supraceliac, but not infrarenal 
clamping (p < 0.0006). Although levels decreased 
somewhat after this point, they remained signifi- 
cantly higher than in the IRC group during both 
proximal and distal clamping, 1 hour after unclamp- 
ing, and 3 hours after the operation was over (Fig. 
4). t-PA levels were significantly greater during SCC 
(5.3 _+ 0.6 vs 1.2 + 0.2 ng/ml;  p < 0.0001), and 
remained so until 180 minutes after operation ended 
(5 hours after unclamping). An overall comparison of 
all patients' ECLT, fibrinogen, and t-PA after the 
period of proximal clamping is shown in Fig. 5. 
PAl-1 levels were similar in both groups, remain- 
ing close to baseline (20 _+ 4 ng/ml)  until approxi- 
mately 180 minutes into the operation (70 minutes 
after proximal clamping), at which time they in- 
creased. They continued to rise, and peaked, at 180 
and 720 minutcs after surgery, at more than four 
times their baseline value (92 -+ 18 ng/ml; Fig. 6). 
No differences between groups were seen. The de- 
cline in cl2-AP levels was greater in the SCC as 
compared with the IRC group (66% vs 36%, respec- 
tively; p < 0.002), and levels remained lower after 
surgery. Changes in the t-PA to PAI-1 ratio corre- 
sponded temporally to those in the ECLT, pealdng 
immediately after supraceliac clamping a d returning 
to baseline after unclamping (Fig. 7). In the 10 
patients who underwent SCC, maximal t-PA (r = 
0.049, p = 0.90) and shortest ECLT (r = 0.089, p = 
0.81) were not correlated with duration of SCC 
ranging between 20 and 53 minutes. 
DISCUSSION 
These data show that SCC causes hepatocellular 
dysfunction and a primary fibrinolytic state with ele- 
vated t-PA and depressed c~2-AP levels. These 
changes are very consistcnt and occur as early as 20 
minutes after clamping, although the magnitude of 
changes of fibrinolytic mediators do not correlate 
with clamp times per se as long as 53 minutes. Al- 
though thrombocytopcnia, hemodilution, hypother- 
mia, and laboratory changes consistent with con- 
sumptive coagulopathy occur in all patients, there are 
no differences in any of these parameters according 
to clamp position. 
t-PA, the fibrinolytic activator responsible for the 
cleavage of plasminogen to plasmin, is rapidly re- 
leased by endothelial cells in response to venous 
occlusion, exercise, endotoxin, and arterial isch- 
emia. l°-12 Plasminogen activator inhibitor (PAI)-I, 
an acute phase reactant and the major inhibitor of 
JOURNAL OF VASCULAR SURGERY 
Volume 25, Number 2 Illig et al. 249 
Minutes 
180 
150 
90 
60 
• [] 
30'  
0 
500" 
450- 
400" 
350- • [] 
300- 
• 250- 
200- 
__on_ 
150- 
100- 
50- 
I I o 
m aL 
120 
• [] 
I I 
ng/mL 
:t" e 
:1, 
5-  
| 
3-  
2" • " 
0 
SCC IRC SCC IRC SCC IRC 
ECLT Fibrinogen t-PA 
Fig. 5. Individual data points for ECLT, fibrinogen, and t-PA after proximal clamping (sample 
T3) in patients who underwent SCC and IRC. Normal values are shown by the shaded areas, 
and mean value for each group is shown by dotted line. 
140 
t28 
100 
.~ 88 
"7 6O 
4O 
20 
100 
8o 
~8o 
0. 40 <, 
20 
p<.002 by RM ANOVA 
* p<.025 by t-test 
v i vv 
I 
Clamps on 
~,~ 0 100 200 300 400 975 ~vv ouu ~vv  
] Mean time {minutes) ] I Mean time (min~es) 
Unc~mped Clam~ on Undamped 
Fig. 6. PM-1 (left) and a2-AP levels (right) during study protocol. Data presented as mean + 
standard error. Overall significance assessed by repeated measures ANOVA, and each point in 
time is analyzed using t tests. *Significance at p < 0.025 (because of multiple comparisons). 
SCc 
"-El- IRe 
[ ]  Proximal clamp on 
[ ]  Distal clamp only 
t-PA, is produced by vascular endothelial and 
smooth muscle cells, platelets, and hepatocytes in 
response to sepsis, exposure to various cytokines, 
operation , and trauma.12-19 PM- 1 normally increases 
in parallel with t-PA, although the increase in PAI-1 
is usually delayed relative to that of t-PA. 6,1°,12,17 
c~2-AP is also synthesized by the liver, and binds to 
and inactivates plasmin. 2° t-PA is inactivated in two 
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major ways: complex formation and inactivation by 
PAI-], and first-pass, PAI-l-independent hepatic 
clearance. 11,21-23 The ratio of t-PA to PAI-1 is an 
index of free t-PA able to initiate fibrinolysis, s,24 
In the present study, t-PA levels were consistently 
elevated in patients who underwent SCC. We do not 
have data to determine whether production was in- 
creased or dcgadation decreased (or both). Because 
t-PA release is known to occur in response to isch- 
ema, however, and because hepatic degradation is a 
major pathway for its removal, both increased pro- 
duction and reduced degradation could reasonably 
be assumed to occur when the aorta is clamped above 
the level of the celiac and superior mesenteric arter- 
ies. In addition, because PAl-1 is produced, in part, 
by hcpatocytes, the hepatic ischemia produced by 
SCC could contribute o the delay in PAl-1 eleva- 
tion. Indeed, PAI-1 levels are low during the anhe- 
patic phase of OLT and do not rise until reperfusion, 
despite elevated t-PA levels. 6 In the present s udy, 
accelerated fibrinolysis, as indicated by a depressed 
ECLT, occurred only during the period of time 
when PAl-1 levels were not yet elevated and blood 
flow through the liver was prevented, soon after 
supraceliac clamping. The fall in a2-AP may simply 
reflect consumption due to binding with the high 
levels ofplasmin rather than being a primary event. 
Despite elevated t-PA levels, most patients who 
undergo SCC do not develop a coagulopathy that 
results in abnormal bleeding, probably because he- 
patic reperfusion and the delayed increase in PAI-1 
levels quickly reduce t-PA activity. We hypothesize 
F 
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Net: 
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Delayed ~, PAl-1 
,~ ~2-AP 
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Primary Fibrinolysis 
Fig. 8. Schematic summary of h pothesized changes oc- 
curring after SCC leading to primary fibrinolytic state. 
that if an insult were to occur in this setting, how- 
ever, producing either prolonged hepatic ischemia or 
dysfunction or derangements in the activator-to-in- 
hibitor balance, fibrinolysis could persist or worsen. 
Thus, intraoperative or postoperative hypotension, 
acidosis, or hypothermia, for example, could poten- 
tiate this fibrinolytic state and lead to clinically rele- 
vant hemorrhage. 
Differentiation between activation of the entire 
coagulation pathway with concomitant secondary fi-
brinolysis (so-called "consumptive coagulopathy") 
from fibrinolysis occurring as a primary event can be 
difficult. In the present study, some activation of 
coagulation occurred in all patients, reflected by re- 
duced fibrinogen and platelets, increased PT and 
PTT, and increased D-dimer and FDP. No differ- 
ences were observed, however, according to clamp 
position. In contrast, levels ofplasminogen activators 
(t-PA) and inhibitors (~2-antiplasmin) were signifi- 
cantly different in the patients who underwent SCC 
as compared with those who underwent IRC (Fig. 
8). Laboratory abnormalities consistent with con- 
sumptive coagulopathy have been shown to exist 
before surgery in otherwise healthy patients with 
AAA in general, although, for the most part, these 
abnormalities are without clinical significance. 2s,26 
Cohen et al. demonstrated that SCC in dogs pro- 
duces elevated PT and PTT, elevated FDP, and re- 
duced fibrinogen. These abnormalities were revers- 
ible by perfusion of the small bowel, and they 
hypothesized that bleeding after SCC was due to 
consumptive coagulopathy caused by gut ischemia. 
Fibrinolytic mediators, however, were not measured, 
and clamp times required to produce these changes 
were longer than those observed here. 27"29 
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These data demonstrate that supraceliac lamp- 
ing consistently causes a primary fibrinolytic state 
caused by high levels of endogenous t-PA without 
concomitant elevation in its major inhibitor, PAI-1. 
Hepatic hypoperfusion may be the primary cause, 
accounting for a reduction in t-PA degradation and 
explaining the temporal lag in PAI-1 elevation. I f  so, 
this phenomenon would be xpected to occur in any 
situation that leads to hepatic ischemia. I f  clinically 
relevant bleeding occurs despite adequate replace- 
ment  therapy, treatment with antifibrinolytic agents 
should be considered. 
We thank Cathy Cimino and Fcng Qin, MD, for their 
expert echnical assistance. 
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DISCUSSION 
Dr. Jon R. Cohen (New Hyde Park, N.Y.). In 1986 
the late Dr. Crawford and his associates reported on 605 
TAA repairs with a remarkable operative mortality rate of 
8.9%. A clamping time greater than 60 minutes was one of 
three statistically significant factors in their analysis for the 
prediction of patient death. Even more important, postop- 
erative bleeding required reoperation in 9% of their pa- 
tients, of whom one third died of blood loss or of compli- 
cations related to blood loss. Overall, 25% of the early 
deaths were directly attributed to intraoperative and post- 
operative bleeding. Bleeding is almost always associated in 
these cases with a coagulopathy and not with technical errors 
in the repair. The coagulopathy usually begins after aortic 
unclamping and is related to the time of cross-clamping. 
For those of you in the audience who have not had the 
pleasure of standing in an operating room during TAA 
repair, coming off the cross-clamp and finding yourself 
knee-deep in blood with the blood running out the door 
and down the hall, and you're not sure what to do, we 
attempted to specifically address this problem. We took it 
into the laboratory, and over a series of 3 years performed 
four different sets of experiments to look at SCC that 
resulted in disseminated intravascular coagulation (DIC) 
that was directly related to the ischemia nd reperfusion of 
the small bowel through the superior mesenteric artery. 
Intestinal permeability dramatically increased as a result of 
the superior mesenteric artery occlusion, and reperfusion 
of the superior mesenteric artery was the major nidus for 
the development ofDIC. 
The current paper demonstrates that SCC induces a 
primary fibrinolytic state. The authors postulate that he- 
patic ischemia leads to hepatocellular injury, which results 
in insufficient clearance oft-PA. This is in direct contradic- 
tion to our laboratory studies, which indicated that, in fact, 
the liver was not the cause of the coagulopathy. There are 
several major problems when interpreting the data from 
this study. All of the 10 patients who had SCC did not have 
TAAs and all were heparinized. We have never heparinized 
patients who are undergoing TAA repair, and I would 
venture to guess that most surgeons who routinely per- 
form this type of surgery do not routinely heparinize their 
patients because of the fear of the bleeding that we are 
describing. 
There are several questions and comments I have for 
the authors. You relate that the total blood loss between 
the SCC group and the IRC group was not significantly 
different, with 3100 ml in one group and 3000 ml in the 
other group. Yet there is a significant difference in the 
amount of blood transfused between the two groups at 
1300 ml in the SCC group and 860 ml in the IRC group. 
How do you account for the minimal differences in re- 
corded blood loss yet the significant difference in the 
amount of blood transfused? 
Although you report that SCC produces a primary 
fibrinolytic state, there was no difference in the blood loss 
between the two groups. How do you reconcile these two 
observations? 
If the fibrinolytic state was significant, hen the amount 
of blood lost should have been greater. I would conclude 
that although a fibrinolytic state may exist, it may not be 
clinically relevant and may not be the cause of bleeding 
seen during TAA repair. 
You recommended that if clinically relevant bleeding 
occurs despite the patient being given adequate replace- 
ment therapy, antifibrinolytic agents should be given. 
What kind of agents and at what time during the procedure 
are you recommending that they be given? 
Unfortunately, I would have to conclude that al- 
though the observations are interesting, they do not corre- 
late with the clinical observations that occur during pro- 
longed cross-clamping for TAA repair. I believe that the 
study group is too small and the range of cross-clamp times 
and bleeding too great to make significant conclusions 
about whether or not hepatic ischemia or primary fibrino- 
lysis contributes to the bleeding seen in these type of cases. 
Dr. Karl A. Illig. Dr. Cohen's work conducted in the 
late 1980s and early 1990s was the impetus for our interest 
and ongoing experiments in this topic, and we have relied 
to a significant extent on his previous work. 
One of Dr. Cohen's major points is that in his studies 
in dogs the effect that his group saw seemed to be DIC - 
rather than primary fibrinolysis. A second major point was 
that this effect was ameliorated by perfusion of the superior 
mesenteric artery rather than the celiac artery. 
One obvious difference between Dr. Cohen's work and 
our study is that at the rime that Dr. Cohen's tudies were 
being conducted, primary indicators offibrinolysis, uch as 
t-PA, PAI-1, and a!pha-2 antiplasmin, were not measured. 
The other difference, one that we recognized quite early, is 
that if hepatic hypoperfusion is the primary problem, as we 
suggest here, why is it then that Dr. Cohen was able to 
reverse his changes by perfusing the superior mesenteric 
artery and not the celiac artery? 
Obviously, by perfusing the superior mesenteric artery, 
all of that blood then funnels through the portal vein into 
the liver. In a stoichiometric sense, the majority of blood 
volume flowing through the liver gets there through the 
portal vein. So we think that by perfusing the superior 
mesenteric artery ou are certainly reducing intestinal per- 
meability; however, you are also reversing any potential 
hepatic ischemia that might be there to start with perhaps 
more effectively than by perfusing the celiac artery itself. 
One brief point about the blood loss. The total 
amount of volume and packed cells infused into the patient 
was the same. The only difference was a greater infusion of 
banked blood in the SCC patients, probably because of 
individual variations in cases. Somewhat o our surprise, 
total blood loss was not different. We predicted beforehand 
that it would be. 
We did indeed have no clinical problems in our series. 
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We attribute that to the fact that we were performing an 
experiment in a controlled, prospective fashion here with 
the cooperation a d interest of many services. Simply by 
virtue of the fact that we were paying such close attention 
to these people, no problems occurred. 
When to treat and whether or not to treat patients with 
antifibrinolytic agents are the questions that we are at- 
tempting to answer right now. There are obviously two 
major drugs that can be used, Amicar and aprotinin. We 
are currently working on who should be treated and for 
what indications. What we are attempting to do is to 
separate fibrinolysis that occurs as the primary problem, 
from that that occurs as a result of DIC. In DIC, fibrino- 
lysis is a useful and necessary event hat is required to clear 
microclots from the microcirculation. If we just charge 
ahead there with antifibrinolytic agents, we may be doing 
the patient harm. So the primary question is how to deter- 
mine who is going to benefit from antifibrinolytic agents 
and who is not. 
One final point related to Dr. Cohen's discussion. As 
stated specifically by Dr. Crawford, the majority of people 
who have bleeding problems run into trouble after 60 
minutes of clamping; likewise, in Dr. Cohen's dogs, DIC 
did not occur until 60 minutes of clamping. Our clamp 
times were much shorter than that, averaging 35 minutes. 
We saw the biochemical changes presented here, but again 
did not run into enough elevation to cause clinically appar- 
ent bleeding, perhaps because of limited clamp times. 
Dr. Jonathan P. Gertler (Boston, Mass.). Recently, at 
the Eastern Vascular Society meeting, we reported on 19 
patients who underwent TAA repair with an extremely 
similar survey and very similar results and found an imme- 
diate increase in a tendency toward coagulopathy bio- 
chemically without a clinical correlate to it. What we added 
to the analysis was a study of all coagulation factors in 
addition to PT and PTT. And although I agree with you 
that there is evidence that primary fibtinolysis i  going on; 
we had clear-cut evidence, despite normal PT and PTT of 
factor consumption during the period of visceral cross- 
clamp time. I was wondering whether you would comment 
about that evidence. I think PT and PTT are insensitive to 
some of the early biochemical changes that are present in 
factors that after more prolonged cross-clamp times may 
indeed lend itself to a more diffuse coagulopathy. 
So the issue of whether primary fibrinolysis i occurring 
or whether it is in fact a byproduct of factor consumption, 
such as F1.2, which may in addition spur fibrinolytic activ- 
ity, may be something that the survey ou made use of did 
not completely address. 
In addition, we noticed in some of our patients that 
there was a low normal starting point in factor presence 
and also a high normal tendency to fibrinolysis, and only 
two of those patients went on to prolong their PT and 
PTT, perhaps reflective of some localized intravascular 
coagulation going on before aneurysm repair but a result 
of the aneurysm as has been reported. I was wondering 
whether you saw anything similar. 
Last, when you measured t-PA and PAI-1 immunore- 
activity, did you also measure complex oft-PA/PAI- 1, which 
has a different antigenicity and a different assay and may 
impact on your results in terms of total t-PA and PALl? 
Dr. Illig. We saw your abstract and are looking for- 
ward to the manuscript. To answer your last question first, 
we did not measure the t-PA/PAI-1 complex. It is not 
going to be as simple as being able to say, well, this patient 
has reason A, this patient has reason B, this patient has 
reason C, and so on. In real life, when these patients have 
this ldnd of trouble, they probably do so for a lot of 
different reasons in combination, and factor deficiency is 
certainly something that is important o diagnose and 
treat. 
We did not see any extreme preoperative differences in
any of our variables, but it is something that we have 
thought about at length. As you l~now, there is reasonably 
good evidence that there is increased focal fibrinolytic 
activity in the wall of asymptomatic, run-of-the-mill aneu- 
rysms. Moreover, we are sure that the drop in platelet 
counts as a result of adherence and consumption by the 
implanted graft also contributes. Even when the situation 
is controlled and there is no bleeding, the rise in fibrino- 
lyric mediators and factor deficiencies et the stage. If 
another insult happens after that, such as hypothermia, 
sepsis, or bacterial translocation, a severe, perhaps irrevers- 
ible spiral into coagulopathy can develop. 
Dr. Donald Silver (Columbia, Mo.). I congratulate 
the group from Rochester for this nice paper. I have a few 
questions. 
The major problem is for the surgeon to determine 
whether he or she is dealing with a primary or a secondary 
fibrinolysis. The euglobulin clot lysis time eliminates fi- 
brinolytic inhibitors. Did you obtain any whole blood clot 
lysis times? I also wonder whether you could correlate 
fibrinolytic activity with the level of anticoagulation, for 
instance, were the PTT high or low in relation to the 
euglobulin clot lysis time? And could you correlate the 
fibrinolytic activity with degrees of hepatic ischemia? I 
enjoyed your paper. I think you have raised more questions 
than you've answered. 
Dr. Illig. Thank you very much, Dr. Silver. We did not 
measure whole blood clot lysis times, only euglobulin. Dr. 
Silver raised the interesting question of correlating the 
degree of hepatic ischemia, that is, clamp time, with 
changes in clotting parameters. We deemphasized the issue 
because the study included only 10 subjects. Our clamp 
times ranged between 20 and 53 minutes. When we math- 
ematically correlated SCC time with either the highest or 
the lowest levels of our activators and inhibitors, or highest 
euglobulin clot lysis times, there was no correlation what- 
soever. It was a perfect scattergram with an r value of 
essentially zero. We certainly do not mean to say that 
clamp time has no influence on fibrinolytic mediators, but 
this may suggest that at clamp times up to a certain period 
of time, there is no rush, and it's simply when you exceed a
certain level that things get activated. 
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Dr. Paula K. Shireman (Chicago, Ill.). The question 
I have is concerns why you measured t-PA and PAI-1 
antigen levels rather than their activity, t-PA exists in a 
multiplicity of forms, including single-chain and two-chain, 
and the activity rates for those are vastly different. It seems as 
though activity, when you're testing for a total-body fibrino- 
lyric picture, would be a more sensitive measure than looking 
at the antigen, which could be in a complex form, and there- 
fore inactive, or in a single-chain versus a two-chain form, 
which would have different activities. 
Dr. Illig. We did not measure activity at that point 
simply because of resources available to us at present. 
Dr. David Berridge (Leeds, United Kingdom). Your 
study has shown a significant but transient decrease in 
euglobulin lysis time, and a significant but transient rise the 
in t-PA/PAI-1 ratio, both of which correct themselves 
within 30 minutes of relieving the cross-clamp. In addi- 
tion, neither study has shown a significant increase in 
cross-linked fibrin. Therefore, I am unsure as to whether 
you have any evidence for a significant generalized fibrino- 
lyric state to account for your bleeding. I agree with Dr. 
Cohen that the use of antifibrinolytic agents in such a 
situation is far more likely to cause havoc than to actually 
aid any potential fibrinolytic problem you have with bleed- 
ing. 
Dr. Illig. We certainly can't, on the basis of clamp 
times of this range, yet tell you what's going to happen 
with longer clamp times. This seems to be the perfect 
reason for going back to the laboratory and use experimen- 
tal models in which we can make more aggressive interven- 
tions than we are able to do in our.human patients. 
Dr. E. John Harris, Jr. (Stanford, Calif.). It has 
recently been shown that t-PA is stored in vesicles in 
adrenergic nerve endings and is released with adrenergic 
stimulation. Is the elevated t-PA in your model just merely 
a response to stress, reflecting that there is more stress with 
SCC than IRC? And did you measure catccholamines, 
systemic atecholamines, at the same time as the t-PA to 
correlate that possibility? 
Dr. Illig. That is a very interesting finding that we 
were not aware of, and we will look for that effect in the 
future. 
0 3e~d us rilE MOV£?  
Don' t  miss  a s ingle issue of the journal!  To ensure  prompt  serv ice when you  change your  address ,  
p lease  photocopy  and  complete  th  fo rm below. 
Please send your change of address notification at least six weeks before your move to ensure continued service. 
We regret we cannot guarantee replacement of issues missed ue to late notification. 
JOURNAL TITLE: 
Fill in the title ofthe journal here. 
OLD ADDRESS: 
Affix the address label from a recent issue of the journal here. 
NEW ADDRESS: 
Clearly print your new address here. 
Name 
Address 
City/State/ZIP 
COPY AND MAIL THIS FORM TO: 
Journal  Subscr ipt ion Services 
Mosby-Year  Book, Inc. 
11830 West l ine Industr ia l  Dr. 
St. Louis, MO 63146-3318 
OR FAX TO: 
314-432-1158 
 V Mosby 
OR PHONE: 
1-800-453-4351 
Outs ide the U.S., call 
314-453-4351 
